Stock Financial Ratios, Dividends, Split History

PAHC / Phibro Animal Health Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,602.45
Enterprise Value ($M)1,798.18
Book Value ($M)185.54
Book Value / Share9.37
Price / Book9.52
NCAV ($M)-77.87
NCAV / Share-3.93
Price / NCAV-12.20
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 39,524,000
Common Shares Outstanding 19,261,789
Common Shares Outstanding2 20,626,836
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 40,042,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.16
Return on Assets (ROA)0.11
Return on Equity (ROE)0.71
Balance Sheet (mrq) ($M)
Quick Ratio1.73
Current Ratio3.17
Income Statement (mra) ($M)
Operating Income97.93
Net Income64.61
Earnings Per Share Diluted1.61
Earnings Per Share Basic1.63
Cash Flow Statement (mra) ($M)
Cash From Operations98.39
Cash from Investing-21.94
Cash from Financing98.39
Identifiers and Descriptors
Central Index Key (CIK)1069899
Related CUSIPS

Split History

Stock splits are used by Phibro Animal Health Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Why Is Phibro Animal (PAHC) Up 10.7% Since Its Last Earnings Report?

2018-06-06 zacks
A month has gone by since the last earnings report for Phibro Animal Health Corporation (PAHC - Free Report) . Shares have added about 10.7% in that time frame. (2-0)

Phibro Animal Health's (PAHC) Management on Q3 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Phibro Animal Health Corporation (NASDAQ:PAHC) Q3 2018 Earnings Conference Call May 8, 2018 9:00 AM ET (2-0)

Phibro Animal (PAHC) Q3 Earnings Beat, Sales Improve Y/Y

2018-05-08 zacks
Phibro Animal Health Corporation (PAHC - Free Report) reported adjusted earnings per share (EPS) of 46 cents in the third quarter of fiscal 2018, up 24.3% year over year. Adjusted EPS surpassed the Zacks Consensus Estimate of 44 cents. According to the company, the year-over-year improvement was primarily driven by a higher gross profit, reduced interest expenses and a lower effective income tax rate. (49-0)

5 Stocks Near 52-Week High: Is More Upside Left?

2018-03-28 zacks
A stock at a 52-week high level is considered a winner. This level helps investors decide on whether to buy or sell the stock. Investors often wonder if this level has made the stock overpriced. While they are not totally incorrect, all stocks hitting a 52-week high are not expensive. In fact, in an attempt to avoid stocks that are near their 52-week high levels, an investor might miss out on top gainers. (59-0)

Here's Why Phibro Animal Health is Worth a Buy Right Now

2018-03-20 zacks
Phibro Animal Health Corporation (PAHC - Free Report) has been gaining investor confidence from consistently impressive results. The stock has surged 45.4% over the past year, ahead of the S&P 500’s 17.8% rally and the broader industry’s 17.7% rise. (30-0)

CUSIP: 71742Q106